Vaxart Acquires Decoragen for $15M

TL;DR

Vaxart buys Decoragen for $15M cash to boost gene therapy pipeline.

AI Summary

Vaxart, Inc. announced on January 24, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Decoragen, Inc. for an aggregate purchase price of $15 million in cash. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This acquisition aims to enhance Vaxart's pipeline with Decoragen's gene therapy platform.

Why It Matters

This acquisition could significantly expand Vaxart's therapeutic offerings by integrating Decoragen's gene therapy technology, potentially leading to new treatment options.

Risk Assessment

Risk Level: medium — The acquisition involves a significant cash outlay and integration risks, and the success of Decoragen's technology is yet to be fully proven.

Key Numbers

• $15.0M — Acquisition Price (Cash paid by Vaxart for Decoragen, Inc.)

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• Decoragen, Inc. (company) — Acquired company
• $15 million (dollar_amount) — Aggregate purchase price for Decoragen
• January 24, 2025 (date) — Date of definitive agreement
• first quarter of 2025 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
• $3 billion — nure at Allergan, the company grew from $3 billion in annual revenue to $7 billion through
• $7 billion — ew from $3 billion in annual revenue to $7 billion through organic and acquired growth, in

Filing Documents

• vxrt20250127_8k.htm (8-K) — 33KB
• ex_770955.htm (EX-99.1) — 14KB
• 0001437749-25-001949.txt ( ) — 184KB
• vxrt-20250124.xsd (EX-101.SCH) — 3KB
• vxrt-20250124_def.xml (EX-101.DEF) — 11KB
• vxrt-20250124_lab.xml (EX-101.LAB) — 15KB
• vxrt-20250124_pre.xml (EX-101.PRE) — 11KB
• vxrt20250127_8k_htm.xml (XML) — 3KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Kevin Finney to Board of Directors On January 24, 2025, following a recommendation by the Nominating and Governance Committee of the Board of Directors (the "Board") of Vaxart, Inc. (the "Company"), the Board appointed Kevin Finney to serve on the Board, effective January 28, 2025, until Mr. Finney's successor is elected and qualified, or sooner in the event of his death, resignation, or removal. The Board has determined that Mr. Finney meets the requirements for independence under the applicable listing standards of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended. Mr. Finney was also appointed as a member of the Audit Committee and the Nominating and Governance Committee of the Board. Mr. Finney is an experienced biotech executive and director who has held numerous leadership roles in the healthcare industry, leading companies from early stages of development through to commercialization. Since November 2019, Mr. Finney has served as President, Chief Executive Officer, and Chairman of the board of directors of Autobahn Therapeutics, Inc. Since January 2016, Mr. Finney has also served as vice chairman of the board of directors of Eirion Therapeutics, Inc. Mr. Finney also served on the board of directors of Anterios Inc., Taris Biomedical (now known as Johnson & Johnson) and Eirion Therapeutics. From January 2019 to July 2019, Mr. Finney served as president and chief operating officer of Abide Therapeutics Inc., where he led the acquisition of Abide by H. Lundbeck A/S in 2019. Mr. Finney is also a founder of Zavante Therapeutics, Inc. (now known as Nabriva therapeutics PLC) and served as its chief operating officer. As a founding member, Mr. Finney led the initial financing of Zavante Therapeutics and its operations from inception in June 2015 through its sal

01

Item 7.01. Regulation FD Disclosure. On January 28, 2025, the Company issued a press release announcing the appointment of Mr. Finney as a member of the Board and the resignation of Mr. Yedid from the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated January 28, 2025. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: January 28, 2025 By: /s/ Steven Lo Steven Lo President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR